Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2010 - 2026)

Ionis Pharmaceuticals' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 28.43% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $2.9 billion, a 28.43% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 27.22% from the prior year.
• Total Non-Current Liabilities eased to $2.9 billion in Q1 2026 per IONS's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $3.0 billion in Q4 2025 and bottomed at $1.9 billion in Q3 2024.
• The 5-year median for Total Non-Current Liabilities is $2.3 billion (2024), against an average of $2.3 billion.
• Across the five-year window, Total Non-Current Liabilities fell 26.82% in 2024 and gained 28.43% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.0 billion in 2022, then increased by 6.56% to $2.1 billion in 2023, then increased by 13.1% to $2.4 billion in 2024, then gained by 27.22% to $3.0 billion in 2025, then retreated by 2.54% to $2.9 billion in 2026.
• Per Business Quant, the three latest IONS Total Non-Current Liabilities figures stand at $2.9 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.4 billion (Q3 2025).